Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psoriatic arthritis screening by the dermatologist: development and first validation of the 'PURE-4 scale'.

Journal of the European Academy of Dermatology and Venereology : JEADV·2018
Same author

Transforming Data into Knowledge: How to Improve the Efficiency of Clinical Care?

Yearbook of medical informatics·2017
Same author

On Contributing to the Progress of Medical Informatics as Publisher.

Yearbook of medical informatics·2017
Same author

Troubled Waters: Navigating Unintended Consequences of Health Information Technology.

Yearbook of medical informatics·2016
Same author

2016 updated EULAR evidence-based recommendations for the management of gout.

Annals of the rheumatic diseases·2016
Same author

Silver Anniversary: 25 Editions of the IMIA Yearbook.

Yearbook of medical informatics·2016

Related Experiment Video

Updated: Jun 21, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Rituximab-induced lung disease: A systematic literature review.

H Lioté1, F Lioté, B Séroussi

  • 1Centre de compétence maladies pulmonaires rares, Hôpital -Tenon, Paris, France. huguette.liote@tnn.aphp.fr

The European Respiratory Journal
|July 18, 2009
PubMed
Summary

Rituximab, an anti-CD20 antibody, can cause various lung disorders. Early diagnosis and glucocorticoid treatment are crucial for managing rituximab-induced lung disease, particularly organizing pneumonia.

Related Experiment Videos

Last Updated: Jun 21, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

  • Pulmonology
  • Rheumatology
  • Oncology

Background:

  • The anti-CD20 antibody rituximab is associated with diverse pulmonary complications.
  • Understanding these lung disorders is essential for patient safety and effective treatment.

Purpose of the Study:

  • To review clinical presentations, causality, and management of rituximab-induced lung diseases.
  • To identify patterns and aid in diagnosis and assessment of causality.

Main Methods:

  • A systematic literature review of English-language PubMed reports up to September 2008.
  • Analysis of 45 cases of lung disease attributed to rituximab, focusing on time to onset, symptoms, and treatment response.

Main Results:

  • The most common presentation was acute/subacute hypoxemic organizing pneumonia (37 cases), typically occurring 2 weeks post-infusion and responding to early glucocorticoids.
  • Acute respiratory distress syndrome (5 cases) occurred hours after the first infusion.
  • Macronodular organizing pneumonia (3 cases) presented insidiously long after therapy and responded to steroids.
  • Eight patients died; 13 cases were highly compatible and 32 compatible with rituximab-induced lung disease.

Conclusions:

  • Rituximab-induced lung disease presents with distinct time-to-onset patterns, suggesting different pathogenic mechanisms.
  • Early recognition, diagnosis, and prompt glucocorticoid therapy are vital for favorable outcomes.
  • Closer monitoring between infusions is recommended, especially for patients with prior respiratory issues.